RLYB— Rallybio Corp

Candid, in a reverse merger with RallyBio, to go public

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Stock Splits Matter: What’s Coming Up This Month?

Rallybio to implement 1-for-8 reverse stock split

Rallybio Announces Reverse Stock Split of Common Stock

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?

Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug